<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759628</url>
  </required_header>
  <id_info>
    <org_study_id>91138 - KAUMS</org_study_id>
    <nct_id>NCT01759628</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>The Effect of Helicobacter Pylori Eradication on Liver Function Tests in Subjects With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kashan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study was to evaluate the effect of helicobacter pylori eradication on liver&#xD;
      function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and&#xD;
      anthropometric measurements (body mass index and waist circumference)in subjects with&#xD;
      non-alcoholic fatty liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (HP) antigens have been found in the liver of individuals with benign and&#xD;
      malignant liver diseases. The role of HP in the pathogenesis of non-alcoholic fatty liver&#xD;
      disease (NAFLD) is controversial.&#xD;
&#xD;
      This randomized double blind clinical trial was performed in dyspeptic patients with positive&#xD;
      antibody to HP and the evidence of fatty liver in ultrasonography. After excluding other&#xD;
      causes, participants with persistent elevated serum aminotransferase levels were presumed to&#xD;
      have NAFLD. Those with NAFLD liver fat score greater than (-0.64) and positive urea breath&#xD;
      test (UBT) were enrolled. They were randomly assigned to lifestyle modification alone or&#xD;
      lifestyle modification plus HP eradication groups. Quadruple therapy (omeprazole,&#xD;
      amoxicillin, bismuth subcitrate, and clarithromycin) for HP eradication was performed in two&#xD;
      weeks. HP eradication was documented by UBT. Fasting serum glucose, alanine aminotransferase,&#xD;
      aspartate aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and&#xD;
      low-density lipoprotein, HOMA-IR, and anthropometric measurements (body mass index and waist&#xD;
      circumference) were checked at baseline, eight weeks, and twelve weeks from the beginning of&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline liver function tests at Twelve weeks</measure>
    <time_frame>Twelve weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of insulin resistance and lipid profile during the study period</measure>
    <time_frame>Twelve weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.pylori eradication</intervention_name>
    <description>The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks</description>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <other_name>Helicobacter pylori treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dyspeptic patients with positive antibody to H.pylori and persistent elevated&#xD;
             aminotransferase levels with the evidence of fatty liver in ultrasonography, who were&#xD;
             referred to a gastroenterology clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),&#xD;
             heart disease (ischemic or congestive), hepatic disease (viral hepatitis, autoimmune&#xD;
             hepatitis, wilson disease, hemochromatosis, liver mass lesion), renal disease (serum&#xD;
             creatinine concentration of &gt; 1.5 mg/dl), any severe systemic co-morbidities,&#xD;
             neoplasm, using any hepatotoxic medication during the past 3 months, previous history&#xD;
             of peptic ulcer, previous history of H.pylori eradication, and pregnant or lactating&#xD;
             women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raika Jamali, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology clinic, Sina Hospital (Tehran) / Beheshti Hospital (Kashan)</name>
      <address>
        <city>Tehran / Kashan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Raika Jamali, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Steatohepatitis,</keyword>
  <keyword>Helicobacter pylori,</keyword>
  <keyword>Insulin resistance,</keyword>
  <keyword>Alanine aminotransferase,</keyword>
  <keyword>Aspartate aminotransferase,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

